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Abstract
Introduction: Poorer cancer survival in Indigenous populations contributes to health
inequalities in both New Zealand and Australia.
Methods: We reviewed recent evidence of cancer treatment and outcomes among
Ma¯ori and non-Ma¯ori New Zealanders and examined the range of factors that may
contribute to poorer survival in Ma¯ori.
Results: There is clear evidence that Ma¯ori have poorer cancer survival compared
with other ethnic groups, particularly European New Zealanders. Two recent studies
show that Ma¯ori patients receive poorer quality treatment for cancers of the lung and
colon, even after adjusting for patient factors. These findings suggest the need to
consider how the health-care system as a whole may disadvantage Indigenous patients.
Discussion: We present a framework for considering how inequalities may arise in
the delivery of cancer care, taking account of the health system as a whole – including
the structure and organization of cancer services – as well as treatment processes and
patient factors. A key feature of this framework is that it directs attention towards
system-level factors affecting cancer care, including the location, resourcing and
cultural focus of services. Our analysis suggests a need to look beyond individual
patient factors in order to improve the quality and equity of cancer services and to
optimize cancer survival in Indigenous populations.
Introduction
The differential health status of Indigenous and non-Indigenous
people is an ongoing challenge for the health sector in both Australia
and New Zealand.1–3 Cancer is an important and growing contributor
to these health inequalities4,5 and provides a salient case study for
considering how health services may either reduce or exacerbate
shortfalls in Indigenous health. This article focuses on the experi-
ence of Ma¯ori cancer patients, but such discussion has relevance for
other diseases and for Indigenous populations in Australia (and
Canada) in whom similar patterns have been observed, particularly
in relation to cancer treatment and survival.5–7
Methods
We reviewed recent evidence on cancer treatment and outcomes
among Ma¯ori and non-Ma¯ori New Zealanders and explored possible
factors contributing to poorer survival in Ma¯ori. In doing so, we
sought to look beyond patient-level factors to take account of the
health system as a whole. Our intention is that this analysis will
direct attention to some important areas to address in strengthening
cancer services and ensuring Indigenous and non-Indigenous
populations benefit equally from the health sector’s commitment to
cancer control.
Results
Inequalities in cancer outcomes
While the last 10 years have seen an encouraging reduction in cancer
mortality in New Zealand, inequalities in cancer remain and in some
cases are increasing.8 Total cancer incidence is around 20% higher in
Ma¯ori compared with non-Ma¯ori New Zealanders while mortality is
almost twice as high.9 This disproportionate burden of mortality
occurs because Ma¯ori are not only more likely to develop cancer
(particularly the less treatable types), but also more likely to die from
cancer following diagnosis.9–14
There is clear evidence that Ma¯ori have poorer survival than
other ethnic groups for most types of cancer.9–12,14 (Pacific patients
have poorer cancer survival compared with European patients,
although their outcomes are somewhat better than those of
Ma¯ori.10). Ma¯ori experience a significant survival disadvantage for
almost all the most common cancer sites (including lung, breast
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and colorectum), while Ma¯ori with cancers of the prostate or cervix
are twice as likely to die from their disease compared with their
European or non-Ma¯ori counterparts.9,12,14 The exception to this
pattern is melanoma, for which European patients have little or no
survival advantage.10,11,14
Why do Ma¯ori patients do worse? From a clinical perspective,
differences in both disease and patient characteristics are often seen
as likely contributors to differential outcomes. There is no doubt that
these factors play a role in survival differences between Ma¯ori and
non-Ma¯ori patients – particularly stage at diagnosis, an important
predictor of survival. But do they fully account for the survival gap
between Ma¯ori and non-Ma¯ori, and (even if they do) does this mean
health services are irrelevant to cancer inequalities?
Compared with non-Ma¯ori, Ma¯ori patients are more likely to be
diagnosed with late-stage disease for cancers of the lung, breast,
prostate, colorectum and cervix, and for melanoma.9 As well as
being diagnosed at a later stage, Ma¯ori are also less likely to have
stage at diagnosis recorded.9 While differential stage accounts for
some of the survival difference between Ma¯ori and non-Ma¯ori
patients – particularly for cancers of the breast and prostate – it is
important to note that significant survival differences persist even
after adjustment for stage at diagnosis.9–11
Differences in co-morbidity may also contribute to poorer cancer
outcomes in Ma¯ori patients. Ma¯ori New Zealanders have higher
prevalence of diabetes, cardiovascular and respiratory disease,15 all
of which may limit treatment choices and reduce survival. Reasons
for higher co-morbidity in Indigenous peoples are complex and
include greater socio-economic deprivation, poorer access to favour-
able determinants of health and (ultimately) historical disadvantage
through the processes of colonization.15,16
So do differences in stage at diagnosis and patient co-morbidity
fully explain why Ma¯ori cancer patients have poorer survival?
Research from both New Zealand and Australia suggests not, with
poorer survival in Indigenous patients persisting even after adjust-
ment for both stage and co-morbidity.6,17 Moreover, it is important to
consider why Ma¯ori patients are more likely than non-Ma¯ori to have
co-morbid conditions and less likely to be diagnosed at an early
stage of cancer progression as both factors are potentially responsive
to health care.
Inequalities in cancer treatment
Emerging evidence suggests that Ma¯ori experience particular barri-
ers to accessing diagnostic cancer services. New Zealand’s cancer
screening programmes have lower coverage for Ma¯ori and Pacific
women compared with Europeans.18–20 In addition, Ma¯ori are more
likely to experience unmet need for primary health care (the usual
route to diagnosis for cancers not detected by screening).21–23 Within
primary care, Ma¯ori experience shorter consultation times and are
less likely to be referred for specialist review compared with other
ethnic groups.24 Difficulties in access to and through the health
system are likely to contribute to delayed cancer diagnosis in Ma¯ori
patients.
There is also growing evidence that Ma¯ori patients face barriers to
effective care even after a cancer diagnosis is made. Audit data from
New Zealand’s national breast screening programme suggest Ma¯ori
women wait longer to receive treatment following a diagnosis of
breast cancer.18 Two recent studies show Ma¯ori are less likely than
European patients to receive curative treatment for cancer of the lung
and colon.25,26
Stevens et al. reviewed management of lung cancer in a cohort of
patients diagnosed and treated in Auckland and Northland in 2004.25
They found Ma¯ori patients were significantly less likely than Euro-
peans to receive potentially curative treatment (received by 12% of
Ma¯ori compared with 22% of European patients). This disparity was
not accounted for by differences in disease factors or patient
co-morbidity: after adjustment for age, sex, tumour type and stage,
co-morbidity and small area deprivation, Ma¯ori patients remained
only a third as likely to receive curative treatment (Ma¯ori/European
odds ratio = 0.30, 95% confidence interval (CI) 0.10–0.80). While
Ma¯ori and European patients were equally likely to receive diagnos-
tic and staging investigations, European patients had significantly
shorter waiting times from diagnosis to treatment compared with
Ma¯ori.
Similarly, Hill et al. found significant ethnic differences in treat-
ment of patients with colon cancer.26 Ma¯ori and non-Ma¯ori patients
received similar rates of surgical resection, but Ma¯ori were around a
third less likely to receive adjuvant chemotherapy (Ma¯ori/non-Ma¯ori
ratio = 0.69, 95% CI 0.53–0.91 among patients with stage III
disease). As with lung cancer, there were also significant differences
in the timeliness of treatment: among those receiving adjuvant
chemotherapy over half of all Ma¯ori patients waited 8 weeks or more
to start treatment, compared with a quarter of non-Ma¯ori patients.
Taken together, these findings suggest the health service as a
whole may deliver a lower quality of cancer care to Ma¯ori compared
with non-Ma¯ori patients. This does not mean that individual health
workers or service providers treat their Ma¯ori and non-Ma¯ori
patients any differently (indeed, no New Zealand studies have
explicitly examined this possibility). But at a population level, Ma¯ori
appear to be receiving less curative cancer treatment compared with
non-Ma¯ori (particularly European) patients. Inevitably, these differ-
ences in treatment will contribute to poorer cancer outcomes in
Ma¯ori.17
Discussion
Factors contributing to inequalities in cancer
treatment and outcomes
Inequalities in treatment of Ma¯ori and non-Ma¯ori patients may arise
at three levels: differences in individual patient factors, differences
in health-care processes and differences in the function of the health
system as a whole in relation to Ma¯ori and non-Ma¯ori populations
(Table 1).27–29
Clinicians are likely to be most familiar with those factors that
operate at the level of individual patients, as these are the factors
most visible in the clinical encounter. Less apparent but equally
important are factors operating at the level of health-care processes
(such as referral systems and presentation of treatment options) and
the health system itself (including the location, resourcing and cul-
tural ‘norms’ of services). In practice, these three levels interact, and
some factors may fit under more than one level depending on the
perspective taken. For example, capacity to meet the costs associated
with receiving care may be considered either a system- or a patient-
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level factor, depending on whether one focuses on the provision and
funding of services or the capacity of individual patients to meet
treatment-related costs.
Patient factors
Ma¯ori New Zealanders have higher co-morbidity compared with
other ethnic groups,15,21 which may affect their treatment options.30,31
Yet both recent studies of cancer treatment found Ma¯ori
patients received lower rates of curative intervention even after
adjustment for co-morbidity.25,26 Co-morbidity is not necessarily a
contraindication to treatment such as chemotherapy, which confers
significant survival advantage even in the presence of pre-existing
medical conditions.32,33 Withholding potentially curative treatment
in the presence of co-morbidity will disproportionately disadvantage
groups with higher levels of coexisting disease. Patient co-morbidity
may interact with other factors – including communication difficul-
ties and cultural differences between patients and health-care pro-
viders – to decrease the likelihood of Ma¯ori patients being offered
treatment.
Ethnic differences in treatment are often attributed to patient
choice, yet neither study found evidence that this contributed to
differences in interventions between Ma¯ori and non-Ma¯ori cancer
patients.25,26 While Ma¯ori patients were reported as slightly more
likely to refuse treatment for lung cancer (13% of Ma¯ori compared
with 9% of all patients), this did not explain their lower rate of
curative treatment.25 No ethnic differences in treatment preference
were found among patients with colon cancer.26
Some researchers have suggested that ethnic minorities are more
likely to use alternative therapies and therefore reject mainstream
treatment, but there is little evidence to support this in the New
Zealand context,34,35 and care should be taken to avoid patient stere-
otyping.36,37 Recent qualitative research shows many Ma¯ori are com-
fortable combining clinical treatment with more traditional forms of
healing, seeing these as complementary rather than mutually exclu-
sive.38 Patients of all ethnicities are less likely to accept health care
if they perceive the disadvantages as outweighing the advantages.34
Where health services experience recurrent difficulty in engaging
with patients from a particular ethnic group, questions must be
raised about the cultural safety of those services,39 the context
in which patients are making health-care decisions, and past
interactions between service providers and the population group in
question.40
As in Australia, New Zealand’s Indigenous population experi-
ences significant socio-economic disadvantage relative to other
ethnic groups (particularly Europeans).15 Deprivation is associated
with later stage diagnosis and poorer access to cancer treatment.41 As
noted earlier, socio-economic disparities in care may be considered
both a patient- and a system-level factor as cost-related barriers
reflect an interaction between patient circumstances and the funding
and delivery of services.
Treatment processes
Cancer care is complex, often involving multiple specialities, refer-
ral pathways and service providers. This complexity poses chal-
lenges for all patients, but Ma¯ori appear particularly disadvantaged.
Hill et al. found Ma¯ori with stage III colon cancer were 30% less
likely to receive adjuvant chemotherapy compared with non-Ma¯ori
patients, even after adjustment for co-morbidity.26 There was no
single step in the treatment process at which Ma¯ori received dra-
matically less care than non-Ma¯ori (Fig. 1); rather, the picture is one
of subtle but accumulating disadvantage, ultimately producing a
substantial treatment disparity with chemotherapy offered to only
50% of Ma¯ori patients (compared with 64% of non-Ma¯ori), and
Ma¯ori twice as likely to wait 8 weeks or more to start chemotherapy.
Ma¯ori may be disadvantaged by unconscious stereotyping on the
part of health workers. Evidence from the USA suggests stereotyp-
ing on the part of health professionals makes an important contribu-
tion to ethnic inequalities in treatment.42 The influence of
stereotyping may be particularly pronounced in the presence of
uncertainty and time pressure43,44 – features that characterize many
clinical encounters, particularly in cancer care.45 To date, no New
Zealand studies have explicitly examined the role of discrimination
in clinical decision-making, although there is evidence that some
health-care workers have negative stereotypes concerning Ma¯ori
patients,35,37 and Ma¯ori are more likely than Europeans to experience
discrimination by a health professional because of their ethnicity;46
this is associated with lower odds of breast or cervical screening, and
negative health-care experiences.
Communication issues are a recurrent theme in qualitative studies
of health-care experiences among Ma¯ori.35,38 Effective communica-
tion is important for patients from all social groups, but health
workers often find this more difficult with patients from back-
grounds different to their own.24 Such difficulties may prevent
doctors from eliciting complete information from their patients,
making them more likely to rely on stereotypes and less likely to
seek clarification from the patient or their family.47
Health system factors
Service location, funding and the cultural focus of providers may all
contribute to inequalities in treatment. These factors reflect the entire
health system rather than decisions or actions of individual health
workers. Such ‘institutional’ characteristics influence all levels of the
health system and can have a profound effect on the equity of care
offered to different population groups.
A review of cancer services in New Zealand identified a number
of system-level factors that may contribute to lower quality care for
Ma¯ori patients.40 These include the location of cancer services, the
expense of care, the composition of the cancer care workforce and a
Table 1 Factors affecting equity of cancer treatment for different ethnic
groups
Domain Specific factors
Structural and
system-level factors
Location and resourcing of health
services
Health service funding
Cultural focus of health providers
Health-care processes Complex, multi-stepped processes
Health worker reliance on
stereotypes
Communication
Patient factors Co-morbidity, stage at diagnosis
Socio-economic status
Patient preferences
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tendency for cancer services to focus on the total population without
addressing the needs of some ethnic groups.
Patient access is influenced by the location of services35,40 – par-
ticularly cancer centres – which are concentrated in New Zealand’s
main population centres. Centralization may increase the overall
quality of care, yet may also exacerbate inequalities in access for
some population groups. Ma¯ori are more likely to live in rural areas
at greater distance from New Zealand’s six cancer centres.48
The effect of centralization on inequalities will partly reflect what
support is provided to patients and families obliged to travel away
from home to receive care. The absence of ethnic inequalities in
survival from childhood cancer49 suggests it is possible to address
the access barriers faced by Ma¯ori. Paediatric cancer services in
Aotearoa are highly centralized, with most patients and wha¯nau
remaining at specialist cancer centres throughout the acute phase of
treatment (N. Douglas, pers. comm., 2008). The special status of
childhood cancer may attract higher levels of systemic support for
patients and their families, while relatively small patient numbers
may reduce potential for ‘slippage’ in referral and support systems.
Decreased funding for cancer services is likely to impact on
waiting times and service quality, and may differentially reduce the
accessibility of care for those in less affluent groups. While public
hospitals provide the majority of cancer treatment in New Zealand,
a quarter of patients with colon cancer use the private system for
some aspect of their care.50 Private care may offer advantages in
terms of shorter waiting times and possibly better outcomes com-
pared with secondary public services.17 Ma¯ori/non-Ma¯ori differ-
ences in private cancer care are greater than the ethnic gap in
insurance coverage (26% among Ma¯ori and 43% among Pa¯keha¯ in
the 2002–2003 New Zealand health survey51), suggesting that in the
absence of insurance, non-Ma¯ori may be more likely to pay for
private care. This suggests non-Ma¯ori may be better able to ‘buy out’
of geographical disadvantage in cancer care – for example, by
paying for private investigation and diagnosis rather than depending
on non-specialist public services.
Cancer treatment also involves substantial indirect costs. A third
of families with children undergoing cancer treatment have to
borrow money to meet financial commitments associated with
care.52 For adults, cancer treatment often requires time off work.
These factors will disproportionately impact on Ma¯ori, who have
fewer financial resources and are more likely to be in insecure or in
casual employment compared with other New Zealanders.15,53
Specialist cancer treatment in New Zealand is delivered through
mainstream providers, who also provide the majority of cancer
support services. The previously mentioned review found that most
services focus on the total population and reflect European cultural
norms40 – perhaps unsurprisingly, given the dominance of Europeans
and under-representation of other ethnic groups within the health
workforce.54 This mainstream focus in health-care provision may
inadvertently neglect the needs of Indigenous and ethnic minority
groups.
Conclusions
Questioning the fairness of our health system is an uncomfortable
undertaking. The principle of care based on need is a core value for
most health professionals, particularly in the context of a life-
threatening disease. None of us wants to believe that our health
system – or those of us working in it – might discriminate on the
basis of ethnicity. Yet an honest look at the evidence makes it
difficult to avoid this assessment.
An important and potentially illuminating feature of the frame-
work presented here is that it looks beyond individual patients and
health workers to consider the role of the health system as a whole.
We have no evidence that individual health professionals provide
differential care to Ma¯ori and non-Ma¯ori patients; yet the evidence
shows the system as a whole is delivering unequal care. This leads us
to examine features of the health system itself to consider whether
these might result in a kind of organizational discrimination – also
known as institutional racism.55
Fig. 1. Oncology referral, review, offer
and receipt of chemotherapy in Ma¯ori
and non-Ma¯ori patients with stage III
colon cancer, 1996–2003. Percentages
are standardized for age (25–64, 65–74
and 75 years and over) and sex.
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The organization, location, funding and staffing of cancer services
may all contribute to inequalities in the care of Ma¯ori and non-Ma¯ori
patients. Many of these features reflect the historical development of
New Zealand’s health system, and are less a product of contempo-
rary decision-making than a failure to recognize and reverse the
long-standing effects of past decisions. Yet we have the opportunity
to address these institutional factors by considering and changing the
way in which care is offered in the future. To ignore this opportunity
is to accept a health system that provides poorer treatment to those
patients with greatest need.
While health service structures underpin the delivery of cancer
care, provider–patient interactions and clinical decision-making
are also important for equity of care. Each of us may benefit
from examining our practice and asking whether the care we
provide (or the decisions we make, or the research we undertake)
meets the needs of all patient groups, and not just the most visible.
For example, it is important to ensure patients are offered
all appropriate cancer treatment and that chemotherapy is not
withheld unnecessarily in those with pre-existing medical
conditions.
There are success stories in the treatment and care of Ma¯ori
patients, offering potentially important lessons and reminding us
that inequalities are not inevitable. As noted earlier, New Zealand’s
paediatric cancer services deliver high-quality care to all population
groups, with Ma¯ori children enjoying the same outcomes as non-
Ma¯ori.49 Since the introduction of a national screening programme,
Ma¯ori/non-Ma¯ori inequalities in the incidence of cervical cancer
have diminished.8 And while breast screening coverage remains
unequal, some regions have successfully increased their coverage
among Ma¯ori women.18 It is to be hoped that early detection of other
cancers will also improve following advances in access to primary
health care.21–23
In order to recognize the strengths and address the weakness of
cancer services, we need information on health system performance
– including data disaggregated by ethnicity. BreastScreen Aotearoa
(the national breast cancer screening programme) is an example of
good practice in this area, with independent reporting on coverage
by ethnicity.18–20 Inclusion of such data in all routine cancer service
monitoring would be a positive step. Quality improvement systems
also offer a potential tool for improving equity across population
groups, providing information is communicated back to staff
in a timely and effective way. Finally, increased attention to
workforce planning and support for Ma¯ori participation will
help build a health system more responsive to the needs of Ma¯ori
communities.
There is much to celebrate in New Zealand’s cancer services.
Many doctors, nurses, allied health professionals and volunteers
work hard to provide high-quality, compassionate care to patients
and families living with cancer, often in a context of limited time and
resources. While recognizing the strengths of our health system –
and particularly its staff – it is also important for us to recognize that
this system does not always provide equal care to Ma¯ori and non-
Ma¯ori, and that these inequalities contribute to poorer survival for
Ma¯ori with cancer. Inequalities in cancer treatment and survival can
be addressed, but only if we are prepared to ask some difficult
questions.
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